Evidence for the role of purinergic signaling (via P1 and P2Y receptors) in the proliferation of vascular smooth muscle and endothelial cells is reviewed. The involvement of the mitogen-activated protein kinase second-messenger cascade in this action is clearly implicated, although details of the precise intracellular pathways involved still remain to be determined. Synergistic actions of purines and pyrimidines with growth factors occur in promoting cell proliferation. Interaction between purinergic signaling for vascular cell proliferation and cell death mediated by P2X 7 receptors is discussed. There is evidence of the release of ATP from endothelial cells, platelets, and sympathetic nerves as well as from damaged cells in atherosclerosis, hypertension, restenosis, and ischemia; furthermore, there is evidence that vascular smooth muscle and endothelial cells proliferate in these pathological conditions. Thus, the involvement of ATP and its breakdown product, adenosine, is implicated; it is hoped that with the development of selective P1 (A 2 ) and P2Y receptor agonists and antagonists, new therapeutic strategies will be explored. (Arterioscler Thromb Vasc Biol. 2002;22:364-373.)
T he roles of nucleotides and nucleosides as extracellular signaling molecules are now well established. 1,2 P1 receptors for adenosine, of which four subtypes (A 1 , A 2A , A 2B , and A 3 ) have been identified, have been distinguished from P2 receptors for ATP/ADP/UTP, 3 and P2 receptors have been divided into P2X ligand-gated ion channel and P2Y G protein-coupled receptor families. Seven subtypes of P2X receptors and 6 subtypes of P2Y receptors have been cloned and characterized. 4 The majority of studies involving purinergic signaling have been concerned with short-term events, such as neurotransmission or secretion. However, there is growing interest in the long-term trophic actions of extracellular nucleotides and nucleosides on cell growth, proliferation, and death. [5] [6] [7] [8] [9] In the vascular system, short-term purinergic signaling events associated with the control of vascular tone by ATP released from nerves and endothelial cells have been clearly demonstrated. 10 -15 However, the migration, proliferation, and death of vascular smooth muscle and endothelial cells play an important role in the development of intimal thickening during arterial diseases, such as arteriosclerosis and restenosis after angioplasty, and in the growth of new vessels that takes place during wound healing and in tumors. 16 -18 Studies indicating that ATP, ADP, UTP, and adenosine play pivotal signaling roles in these long-term events will be discussed in the present review. 19 -21 
Purines and Smooth Muscle Cell Proliferation Adenosine (P1) Receptors
An early study reported that adenosine produces changes in cAMP and DNA synthesis in cultured arterial smooth muscle cells and suggested that this might result in the regulation of cell proliferation. 22 The authors speculated that adenosine could be one of several regulatory factors in the development of atherosclerosis and might also regulate the release of a smooth muscle mitogen, platelet-derived growth factor (PDGF), from platelets. There is now good evidence that adenosine, an ectoenzymatic breakdown product of ATP, does regulate smooth muscle cell proliferation, but as will be discussed, its properties differ from those for ATP and ADP.
Adenosine inhibits vascular smooth muscle cell proliferation by A 2 receptor activation via the elevation of cAMP, 22, 23 and a selective A 2 receptor agonist, 2-octynyladenosine, reduced neointimal thickening in a rat femoral artery injury model. 24 Indeed, cAMP is a known pathway involved in smooth muscle cell growth arrest and in the maintenance of the contractile phenotype. 25 The possibility that a defect in local adenosine production within the vessel wall could contribute to vascular thickening and neointimal formation was explored, 23 and it was proposed that adenosine inhibits the growth of human aortic smooth muscle cells via A 2B receptors. 26 Later, it was demonstrated that adenosine, acting through A 2B receptors, inhibits collagen synthesis by smooth muscle cells, and it was suggested that drugs that modulate adenosine levels may protect against vaso-occlusive disorders by attenuating extracellular matrix synthesis and the cellular hypertrophy of smooth muscle cells. 27 It seems surprising that this role is not shared by A 2A adenosine receptors, which are coupled to the elevation of cAMP and are expressed on vascular smooth muscle, but it may be that the levels of expression of the A 2A receptors are low relative to A 2B receptors in those smooth muscle cells in which the trophic effects of adenosine were investigated. Other inhibitory pathways also exist, inasmuch as sodium butyrate (a small, naturally occurring molecule with demonstrated activity on cell growth and differentiation) and its more stable in vivo analogue, tributyrin, are potent DNA synthesis and cell proliferation inhibitors of vascular smooth muscle 28 by a mechanism not mediated by an elevation of cAMP.
P2 Receptors
ATP and ADP stimulate DNA synthesis and cell proliferation of cultured porcine artery vascular smooth muscle cells, an action that was shown to be mediated by P2Y receptors. 29 It was speculated that this mechanism was involved in the regulation of vascular smooth muscle cell proliferation during embryonic and early postnatal development, after injury, and in arteriosclerosis. It was further suggested that the ATP released from endothelial cells causes not only autocrine mitogenic stimulation of the endothelial cells themselves but also paracrine stimulation of the smooth muscle cells that migrate to the intima after injury. The mitogenic actions of ATP (but not those produced by adenosine) were reduced by indomethacin (indicating that part of the mechanism involves ATP-induced prostaglandin synthesis, as first proposed by Needleman et al, 1974, 30 by downregulation of protein kinase C [PKC], by long-term exposure to phorbol dibutyrate, and by the PKC inhibitor staurosporine). These results suggest that there is a dual mechanism involved in the trophic mitogenic actions of ATP and ADP, namely, arachidonic acid metabolism and PKC.
Exogenous ATP also appears to induce a limited cell cycle progression in arterial smooth muscle cells. 31, 32 It was shown that stimulation of cultured, quiescent, smooth muscle cells induced chronological activation not only of immediate-early but also of delayed-early cell cycle-dependent genes. In contrast, ATP did not increase late G 1 gene mRNA. An increase in c-fos mRNA was also induced by ADP but not by AMP or adenosine. The fact that 2-methylthio-ATP but not ␣,␤-methylene ATP mimicked these responses tends to favor P2Y rather than P2X receptor mediation.
Sympathetic nerves have been shown to exert a trophic influence on vascular smooth muscle. [33] [34] [35] From her studies of pulmonary artery denervated of sympathetic nerves, Bevan 35 concluded that sympathetic transmitters exert slow trophic as well as fast signaling actions on cell growth and division by influencing protein, DNA, and RNA synthesis. Since ATP as well as noradrenaline (NA) and neuropeptide Y (NPY) are known to be released as cotransmitters from sympathetic nerves, 36 this was consistent with the possibility that ATP and/or its breakdown product, adenosine, might be involved in these trophic actions. A study was initiated to examine the relative effects of ATP, NA, and NPY in the incorporation of [ 3 H]thymidine and the cell number and protein content of smooth muscle cells from the rat aorta and vena cava. 37 Compared with NA, NPY, epidermal growth factor, or insulin, ATP was shown to have considerably greater mitogenic effects on vascular smooth muscle. There is also evidence indicating that vascular smooth muscle has trophic actions on the pattern of sympathetic innervation of blood vessels. 34 UTP, a pyrimidine, also has powerful mitogenic actions on vascular smooth muscle, suggesting that P2U receptors might be implicated. 38, 39 Since the mitogenic effects of UTP and ATP were approximately equipotent, with the present knowledge of the pharmacology of P2 receptor subtypes, this would suggest that the receptor involved is either of the P2Y 2 or P2Y 4 subtype. 40 P2Y 4 receptors were identified on spontaneously hypertensive rat (SHR)-derived cultured rat aortic smooth muscle cells, perhaps coupled to mitogenesis via P42/P44 mitogen-activated protein kinase (MAPK). 41 Although these and other studies have reported that UTP is equipotent with ATP in producing mitogenesis of vascular smooth muscle, 37,42-45 a recent report has claimed that UTP, unlike ATP, has an antiproliferative action on human arterial and venous smooth muscle cells derived from internal mammary artery and saphenous vein. 46 There is no obvious explanation for this discrepancy. Either way, it is interesting that flow-induced release of UTP from vascular endothelial cells has been demonstrated, 47 as has ATP. 14, 48 ADP contributes significantly in synergy with the peptide growth factors PDGF, epidermal growth factor, and transforming growth factor-␤, to the platelet-induced proliferation of vascular smooth muscle. 49 The mitogenic effect of ATP on vascular smooth muscle cells was synergistic with other mitogens, including insulin and insulin-like growth factor-1. 29 It is interesting in this respect that amiloride, which is known to inhibit the actions of several growth factors, also inhibited ATP-induced mitogenesis. 37 ATP has also been shown to be a mitogen for human vascular smooth muscle cells. 50 The molecular mechanisms underlying ATP and insulin synergistic stimulation of coronary artery smooth muscle proliferation have been examined. 51 ATP and insulin individually stimulated DNA synthesis 4-and 2-fold, respectively; however, they acted synergistically to stimulate a 17-fold increase. A similar synergistic stimulation of extracellular signal-regulated kinase (ERK) was demonstrated, whereas ATP dramatically reduced the insulin-stimulated AKT (also known as protein kinase B) activation. The authors concluded that their results were consistent with the relieving (by ATP) of an insulin-induced AKT-dependent inhibitory effect on the ERK signaling pathway, leading to synergistic stimulation of coronary artery smooth muscle cell proliferation.
In a study of the mechanisms involved in ATP-induced proliferation of vascular smooth muscle cells, 52 it was shown that P2Y receptor activation of smooth muscle was coupled to a pertussis toxin-insensitive G q protein, triggering phosphoinositide hydrolysis and subsequent activation of PKC, Raf 1, and MAPK. Both 42-and 44-kDa MAPKs were activated, and tyrosine was phosphorylated. Western blot analysis, with the use of PKC isozyme-specific antibodies, indicated that the vascular smooth muscle cells express PKC-␣ and PKC-␦. P2Y receptor stimulation also caused synthesis of c-fos and c-myc mRNAs; Reactive blue 2 (a P2Y-selective antagonist) and staurosporine blocked this effect. A later study presented evidence indicating that ATP-stimulated vascular smooth muscle cell proliferation requires independent ERK and phosphatidylinositol 3-kinase-signaling pathways. 53 Tyrphostin, a specific inhibitor of tyrosine kinase, inhibited DNA synthesis, Fos-protein expression, and cell proliferation of vascular smooth muscle cells but not ATP-induced Ca 2ϩ influx or inositol phosphate production. 54 Stimulation of cultured aortic myocytes with P2Y agonists produced an increase in the amount of membrane-bound small GTPases of the RhoA family and stimulated actin cytoskeleton organization. 45 Cell proliferation and migration are also known to be induced by RhoA activation. 55, 56 There are 2 phenotypes of smooth muscle: the contractile phenotype and the synthetic (proliferative) phenotype. 57 In a study of cultures expressing these 2 phenotypes using quantitative reverse transcription-polymerase chain reaction, it was shown that P2X 1 receptors were strongly expressed in the contractile phenotype. In the synthetic phenotype, the mitogenic P2Y 1 and P2Y 2 receptor transcripts were upregulated 342-and 8-fold, respectively, whereas the contractile P2X 1 receptor was totally downregulated, and the P2Y 4 and P2Y 6 receptors were unchanged. 42 Furthermore, MAPK kinasedependent growth factor induced the upregulation of P2Y 2 receptors in vascular smooth muscle cells, which the authors suggested may be of importance in atherosclerosis and neointimal formation after balloon angioplasty. 43 In a later study, this group showed that inflammatory cytokines, known to be released in atherosclerosis, upregulate P2Y 2 receptors through PKC and cyclooxygenase (but not cAMP), ERK-1 and -2, or P38-dependent pathways. 58 When the endothelial cells of the central ear artery were injured Ն2 times, the smooth muscle cells of the media migrated into the intima and proliferated there between 1 and 3 weeks after the last injury, despite restoration of the endothelium. 59 In rabbits pretreated with dipyridamole, an adenosine-uptake inhibitor, proliferation was limited.
Purines and Vascular Endothelial Cell Proliferation Adenosine (P1) Receptors
Adenosine has been claimed to be an angiogenesis factor in chick chorioallantoic membrane and embryos. 60, 61 In other early studies, long-term administration of adenosine was reported to induce capillary proliferation in the heart, although it was recognized that this effect might be secondary to mechanical factors resulting from an increased blood flow stimulating capillary growth. 62 We know from later studies that ATP is released from endothelial cells during the shear stress produced by changes in blood flow 14, 48, 63, 64 and that there is an ectoenzymatic breakdown of ATP to adenosine. Electrical stimulation of skeletal muscle also resulted in capillary proliferation, as did long-term administration of adenosine. 62 Long-term local application of adenosine induces an increase of capillary diameter in skeletal muscle of anesthetized rabbits. 65 Adenosine has also been shown to induce dose-dependent proliferation of endothelial cells obtained from the aorta, 66 from coronary vessels, 67 and from human umbilical veins, 68 and it has been shown to stimulate canine retinal microvascular endothelial cell migration and tube formation. 69 The action of adenosine in mediating endothelial cell proliferation is mediated by A 2A and A 2B receptors, although an action independent of adenosine receptors has also been suggested. It has been claimed by Sexl et al 70 that the adenosine receptor mediating endothelial cell proliferation of the human umbilical vein is an A 2A subtype acting via a mechanism that is independent of G s and G i . This group went on to show that stimulation of the A 2A receptor activates MAPK on these endothelial cells. 71 An investigation was carried out involving adenosine stimulation of DNA synthesis in endothelial cells by measuring [ 3 H]thymidine incorporation in cultures derived from human umbilical veins. 72 The authors concluded that the results suggest that Na ϩ -H ϩ exchange and phospholipase A 2 are involved in adenosineinduced DNA synthesis independently of adenosine receptor, protein kinase A, or PKC activation. An 8-phenyltheophylline-resistant mitogenic action of adenosine, which was not mimicked by A 1 -and A 2 -selective agonists, was also described in bovine aortic endothelial cells. 66 An intracellular action of adenosine is possible.
Some of the mitogenic effects of adenosine are mediated via the modulation of vascular endothelial growth factor (VEGF) signaling via A 2A and A 2B receptors. Adenosine mediates growth factor expression through the A 2B receptor in human retinal endothelial cells. 73 A 2B activation results in sequential expression of VEGF mRNA, supporting a role for adenosine in initiating the autocrine production of a cascade of growth factors that facilitate new blood vessel formation. The addition of an antisense oligonucleotide complementary to the A 2B receptor mRNA inhibited VEGF production. Augmentation by adenosine of the expression of VEGF has been described in cerebral 74 and retinal 75 microvascular endothelial cells. In the retinal endothelial cells, this involved A 2A receptor activation of the cAMP-dependent protein kinase A pathway. 76 The initial decline in mRNA of receptors for VEGF and of VEGF binding sites during hypoxia was also shown to be antagonized by A 2 receptor blockade. 76 In the most recent study from Grant et al, 77 the selective A 2B receptor antagonists enprofylline and 3-isobutyl-8pyrrolidinoxanthine inhibited 5Ј-(N-ethylcarboxamido)-adenosine (NECA)-stimulated proliferation of human retinal endothelial cells, ERK activation, cell migration, and capillary tube formation. The authors suggested that this may provide a novel approach to the treatment of diseases associated with aberrant neovascularization, such as diabetic retinopathy and the retinopathy of prematurity.
Hypoxia is a potent stimulus to vascular growth and adenosine, and the pyridine metabolite nicotinamide mimics these effects. 78, 79 The P1 (adenosine) antagonist 8-phenyltheophylline prevented stimulation of the proliferation of bovine aortic and coronary vascular endothelial cells caused by hypoxia-conditioned medium or adenosine. 78 The proliferative response of endothelial cells to adenosine has been shown to depend on an increase in cAMP: consistent with actions of adenosine at A 2 receptors, pretreatment of endothelial cells with pertussis toxin blocked adenosineinduced proliferation, indicating that a G i protein might be involved in the mechanism. 80
P2 Receptors
ADP was shown to be one of several agonists that induced cultured endothelial cell migration and proliferation. 81 Angiogenesis (or neovascularization) begins with the migration of endothelial cells, originating from capillaries, into the tissue being vascularized. ADP and, to a lesser extent, adenosine and adenine showed strong chemotactic activity and were postulated to be angiogenesis factors in vivo. 82 Adenine nucleotides were shown to have a mitogenic action on aortic endothelial cells, probably via P2Y receptors; adenosine, inosine, and hypoxanthine also had mitogenic actions, but apparently they were not via A 1 or A 2 purinoceptor subtypes. 83 ATP has also been shown to produce proliferation of cultured bovine corneal endothelial cells. 84 The source of the purines involved in these trophic actions is largely from the endothelial cells, suggesting an autocrine mechanism. 85 ADP released from aggregating platelets may also play a role. 86 When glomerular capillary or aortic endothelial cells were cultured in polypropylene hollow fibers perfused for 9 days, the endothelial cells formed adherent confluent monolayers with chronic flow, simulating shear stress, but not without flow. 87 Furthermore, the aortic, but not capillary, endothelial cells aligned themselves in the direction of flow. Since (as has been described earlier) ATP is released from endothelial cells by shear stress and because ATP can induce cell migration and proliferation, an involvement of ATP in these trophic changes is indicated. Similarly, mechanical scratching of cell monolayers of bovine pulmonary arterial endothelial cell cultures (which would lead to the release of ATP) induces surviving cells near the wound edge to move and proliferate. 88 Stretch-induced changes in endothelial cell shape 89 and changes produced by hypoxic stress 60 may be mediated by the ATP (and/or adenosine after ectoenzymatic breakdown) released from endothelial cells under both these conditions.
There is evidence at present for P2Y 1 , P2Y 2 , and P2Y 4 receptor subtypes on endothelial cells mediating the release of NO, endothelium-derived hyperpolarizing factor, and prostanoids 4,15,90,91 ; there is also recent evidence for the presence of P2X 2 , P2X 3 , and P2X 4 subtypes in the endothelium 92-95 (Figure 1) .The functions of the P2X receptors are not yet clear, although they appear to be involved in cell adhesion and gap junction formation. Less is known about which P2 receptor subtypes are involved in the mitogenic actions of nucleotides or, indeed, about the mechanisms underlying their effects.
In a study of the EAhy 926 endothelial cell line, it has been shown that ATP and UTP activate the 42-kDa isoform of MAPK and that this activation is regulated by PKC, using both calcium-dependent and -independent mechanisms, but that G i protein is not involved. 96 Regulation of rat brain capillary endothelial cells via P2Y receptors (probably P2Y 2 and/or P2Y 4 , since UTP was equipotent with ATP) has been shown to be coupled to Ca 2ϩ , phospholipase C (PLC), and MAPK. 97 In cultured endothelial cells from guinea pig cardiac vasculature, UTP and VEGF were mitogenic and chemotactic factors. 44 The possibility that UTP was acting indirectly via VEGF was not examined.
Activation of kinases (including the p42/44 MAPK and c-Jun N-terminal kinase [JNK]) may underlie the sustained effects of ATP and UTP on endothelial cells and smooth muscle, such as increased cell proliferation; by use of the EAhy 926 endothelial cell line, UTP and ATP, but not UDP, inhibited tumor necrosis factor-␣ (TNF␣)-stimulated stressactivated protein kinase activity. 98
Vascular Cell Death
There is increasing evidence that cell proliferation and programmed cell death (apoptosis) are linked. For example, VEGF turns on cell proliferation but inhibits apoptosis. 99 Distinct signal transduction cascades, composed of at least 3 protein kinases, mediate cell proliferation and differentiation, growth arrest, and apoptosis. 100 In diseases such as carcinogenesis, degenerative disorders, and ischemia/reperfusion injury, there is an imbalance between cell division and cell death. . Short-term (acute) purinergic signaling controlling vascular tone. Schematic diagram illustrating the main receptor subtypes for purine and pyrimidines present in most blood vessels. Perivascular nerves in the adventitia release ATP as cotransmitter: ATP is released with NA and NPY from sympathetic nerves to act at smooth muscle P2X 1 receptors and, in some vessels, P2X 2 and P2X 4 purinoceptors, resulting in vasoconstriction; ATP is released with calcitonin generelated peptide (CGRP) and substance P (SP) from sensory nerves during "axon reflex" activity to act on smooth muscle P2Y purinoceptors, resulting in vasodilatation. P1 (A 1 ) purinoceptors on nerve terminals of sympathetic and sensory nerves mediate adenosine (arising from enzymatic breakdown of ATP) modulation of transmitter release. P2X 3 purinoceptors are present on a subpopulation of sensory nerve terminals. P1 (A 2 ) purinoceptors on vascular smooth muscle mediate vasodilatation. Endothelial cells release ATP and UTP during shear stress and hypoxia to act on P2Y 1 , P2Y 2 , and sometimes P2Y 4 purinoceptors, leading to the production of NO and subsequent vasodilatation. ATP, after its release from aggregating platelets, also acts on these endothelial receptors. Blood-borne platelets possess P2Y 1 and P2Y 12 ADP-selective purinoceptors as well as P2X 1 receptors, whereas immune cells of various kinds possess P2X 7 as well as P2X 1 , P2Y 1 , and P2X 2 purinoceptors. P2X 2 , P2X 3 , and P2X 4 receptors have also recently been identified on endothelial cell membranes. (Figure is Interactions between purinergic signaling for proliferation and cell death also occur. 101 An example is the turnover of keratinocytes in the squamous epithelium of the epidermis, where there is a continuous progression from cell proliferation in cells at the base of the stratum spinosum (labeled with P2Y 1 receptors) to differentiating keratinocytes (labeled with P2X 5 receptors), which gradually flatten as they reach the stratum corneum, where they become apoptotic (labeled with P2X 7 receptors), and the dead cells slough off at the skin surface. 102 A similar relationship between proliferation and differentiation (P2X 5 receptor-labeled cells) and apoptotic cell death (P2X 7 -labeled cells) has been shown during the turnover of intestinal epithelial cells. 103 P2X 7 and P1 receptors have been linked to apoptosis in other cell types, particularly immune cells, astrocytes, and thymocytes. 104 -106 Extracellular ATP and adenosine have been shown to cause apoptosis of pulmonary artery endothelial cells. 107 Since the nucleoside transport inhibits dipyridamole, prevented ATP-induced DNA cleavage, it seems likely that apoptosis is mediated by the intracellular actions of adenosine rather than through surface receptors, as later reported for apoptosis in HL-60 cells. 108 The adenosine metabolites, inosine, hypoxanthine, and xanthine, do not cause apoptosis, although S-adenosylhomocysteine hydrolase inhibitors also cause DNA fragmentation that is typical of apoptosis. The authors speculate that ATP released from cells undergoing cytolysis or degranulation may cause endothelial cell death and that this may be important in acute vascular injury or in limiting angiogenesis. A later report from this group examined the mechanism of purine-induced apoptosis in pulmonary artery endothelial cells and showed that inhibition of methyltransferase activity is involved. 109 ATP converts necrosis to apoptosis in oxidant-injured bovine pulmonary artery endothelial cells. 110 Apoptosis serves an important role in the economy of tissues by eliminating cells without the attendant risks of an acute inflammatory response associated with necrosis. 111 In a study of porcine aortic endothelial cells, extracellular ATP and ADP, probably acting through P2X 7 receptors, were shown to activate nuclear factor-B, a transcription factor, and induce apoptosis. 112 In another report, extracellular ATP was shown to activate nuclear factor-B through the P2X 7 receptor by selectively targeting P35 (Rel A) in cells of the macrophage lineage. 113
Implications for Vascular Disease
Vascular injury represents a critical initiating event in the pathogenesis of various vascular diseases, including organ transplantation, sepsis, and atherosclerosis, and the events that follow, ie, vascular cell growth, migration, proliferation, and death. 114, 115 Since large amounts of ATP are released from injured cells and because ATP and its breakdown product, adenosine, have potent actions in smooth muscle and endothelial cell growth, migration, proliferation, and death, the possibility that purines are one of the factors involved in the development of vascular disease needs to be considered. Various models of vascular injury have been introduced, including denudation of the endothelium by mechanical injury (balloon or nylon catheters), diet-induced hypercholesterolemic injury, or immune injury. However, only a limited number of studies have been carried out to examine the possible roles of purines in the development of the pathology of vessels.
The growth of new blood vessels takes place in pathological events such as tumor growth, wound healing, psoriasis, and the ischemic retinopathies that occur in diabetes and sickle cell disease. In the adult, the development of new blood vessels, or neovascularization, occurs by budding from existing blood vessels and is referred to as angiogenesis (as distinct from vasculogenesis, which occurs in embryogenic development by vessel formation from mesenchyme precursor cells or angioblasts). Peptide growth factors such as fibroblast growth factor, transforming growth factor-␣, and VEGF are clearly involved in angiogenesis, but as we have seen earlier in the present review, purines and pyrimidines also contribute to this process. 44 In rheumatoid arthritis, new capillary blood vessels invade the joint and destroy the cartilage. In diabetes, new capillaries in the retina invade the vitreous body, bleed, and cause blindness, and tumor growth and metastasis are angiogenesis dependent. 116 Anginal patients treated chronically with dipyridamole to increase adenosine levels showed an increase in coronary angiogenesis, 117 and dipyridamole has also been used for the prevention of stroke. 118 The former action may involve a preferential effect of adenosine on endothelial cells, since smooth muscle proliferation was inhibited in rabbits pretreated with dipyridamole. 59 Apoptotic cell death is recognized to occur in a number of vascular diseases, including atherosclerosis, restenosis, and hypertension. 99, 114 Vascular endothelial cells are continuously exposed to variations in blood flow, which plays an important role in vessel growth or regression and in the local development of atherosclerosis. The shear stress that occurs during changes in blood flow leads to a substantial release of ATP (and UTP) from endothelial cells, 14 and these purines might mediate alterations in the balance between proliferation and apoptosis. 119 Occupation of P2X 7 receptors leads to the production of proinflammatory cytokines, 101 and TNF␣ markedly increases endothelial cell apoptosis via the activation of caspase 3. 99 Atherosclerotic damage results in the disappearance of endothelium-dependent responses to ATP, 120, 121 whereas the relaxing action of smooth muscle is unimpaired. The release of ATP from endothelial cells has been claimed to be impaired in atherosclerotic rat caudal arteries. 122 Long-term supplementation with a high cholesterol diet decreases the release of ATP from the caudal artery of aged rats; there was a significant positive correlation between the unsaturation index of arterial fatty acids and the amount of ATP released and an inverse correlation between the amount of ATP released and blood pressure. 123 Although the roles of endothelial cells and smooth muscle in the pathogenesis of atherosclerosis are still not known precisely, it is known that smooth muscle cells migrate from the media to the intima, where they change to the proliferative phenotype, which leads to thickening of the intima. 124 In restenosis following balloon angioplasty, there is a peak in the proliferation and apoptosis of vascular smooth muscle cells at Ϸ14 days. 125 The first balloon inflation during coronary angioplasty is a preconditioning stimulus leading to a decrease in ischemia during later inflations; intracoronary adenosine administration before coronary angioplasty modi-fies the preconditioning effect of the first inflation. 126 Further studies show that adenosine preconditions human myocardium against ischemia in vivo. 127 The genetic defects underlying hypertension are unknown, but an increase in sympathetic nerve activity is well established, and there is an associated hyperplasia and hypertrophy of arterial walls. 128, 129 An increased release of ATP as a cotransmitter with NA in sympathetic nerves is likely to occur in SHR 130, 131 and may play a role in the trophic changes in the vessel wall. Also, sympathetic neurons innervating the vasculature are dependent on nerve growth factor (NGF) in development, and an increase in NGF gene expression and protein has been described in SHR. 132 ␣,␤-Methylene ATP, an ATP agonist, was shown to increase NGF secretion by vascular smooth muscle cells in SHR. 133 In cultured aortic smooth muscle cells from SHR, responses to UTP and ATP were predominantly via P2Y 4 receptors, and Harper et al 41 have presented evidence to suggest that these receptors are coupled to mitogenesis via p42/p44 MAPK.
Pericytes partially envelop endothelial cells in most capillaries and have been implicated in capillary vasculogenesis and wound repair. 134 In addition, pericytes participate in the negative regulation of endothelial cell proliferation. 135 Along with its stimulating effect on bovine retinal capillary endothelial cells, adenosine has been shown to have an inhibitory effect on retinal pericytes, and it has been hypothesized that this dual function plays a role in the pathological neovascularization process that takes place in diabetes. 136 Diabetic microangiopathy has been implicated as a fundamental fea-ture of the pathological complications of diabetes, including retinopathy, neuropathy, and foot ulceration. 137 Ischemia and hypoxia lead to a substantial release of ATP from endothelial cells, 64 and adenosine is released from hypoxic heart and skeletal muscle. 138 Adenosine has several cardiovascular protective effects in addition to vasodilation, including the promotion of endothelial cell proliferation and an increased expression of VEGF mRNA. 139 Adenosine also appears to play an important role in preconditioning.
When venous segments are transplanted into the arterial tree, the vein smooth muscle proliferates, and within Ϸ2 weeks, it resembles an artery and vice versa. 140 It is possible that ATP (and, subsequently, adenosine), which is released from the damaged cells during the operation and released from endothelial cells in response to the distension produced by increased blood pressure, is involved in the plasticity of change in vessel structure. Endothelial cells spread in response to localized injuries, 141 and ongoing localized injury leads to the release of purines, which might be involved in the repair process. High-velocity bolus doses of intracoronary adenosine have been used successfully as a technique to overcome the slow or "no-reflow" problem that complicates Ϸ10% to 15% of cases of catheter-based revascularization of degenerated saphenous vein bypass grafts. However, the mechanism involved seems likely to be largely the vasodilator actions of adenosine rather than trophic actions producing increased proliferation.
ATP is released from endothelial cells during hypoxia and, together with its breakdown product adenosine, produces vasodilatation and trophic actions on smooth muscle and endothelial cells. It has been proposed that adenosine released in this way may regulate the growth and spread of neoplastic tissues. 142 Evidence that has been presented in support of this hypothesis is that agents (such as dipyridamole) that increase the extracellular levels of adenosine also enhance tumor growth, whereas adenosine receptor antagonists reduce the size of primary tumors and the numbers of metastases. It is also known that tumor cells contain exceptionally high concentrations of ATP 143 and that the damage that occurs when tumors reach a size that leads to the breakage of cells during abrasive movements would release ATP, which might lead to apoptosis via P2X 7 receptors, resulting in tumor regression. 144, 145 Conclusions A summary of the main trophic actions of purine nucleosides and nucleotides and of vascular cell proliferation is shown in Figure 2 . There is compelling evidence that there is regulation of vascular smooth muscle and endothelial cell proliferation by P1 (A 2 ) and P2Y 1 and P2Y 2 receptors that acts through MAPK pathways. However, there is still much to learn about the precise pathways involved; eg, there is only preliminary evidence for the involvement of ERKs and c-Jun N-terminal kinases, and other pathways may also be involved 53, 100, 146 (Figure 3 ). Furthermore, there has been no exploration to determine whether the more recently cloned P2Y receptors, P2Y 11 , P2Y 12 , and P2Y 13 , 147-149 mediate the MAPK pathways that might be involved in vascular cell proliferation. Direct evidence for the involvement of these purinergic mechanisms in atherosclerosis, hypertension, and restenosis is awaited. 
